To test this, we employed Ruxo, an FDA-approved JAK1/2 inhibitor for myeloproliferative neoplasms (MPN), which is also being tested preclinically45,46 and clinically in solid tumors47, as well as in overcoming chemotherapy resistance48,49. This evidence concerns the gene JAK1 and myeloproliferative disorder.